Incidence and outcome of fungal infections in pediatric small bowel transplant recipients

Transplant Infectious Disease

Volumn 12, Issue 6, 2010, Pages 497-504

  Florescu, D F ^a   Islam, K M ^b   Grant, W ^a   Mercer, D F ^a   Langnas, A ^a   Botha, J ^a   Nielsen, B ^a   Kalil, A C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Aspergillus; Candida; Fungal infections; Pediatric transplant; Small bowel transplantation

Indexed keywords

ACICLOVIR; AMPHOTERICIN; AMPHOTERICIN B; BASILIXIMAB; CASPOFUNGIN; COTRIMOXAZOLE; CYTOMEGALOVIRUS ANTIBODY; FLUCONAZOLE; GANCICLOVIR; METHYLPREDNISOLONE; MICAFUNGIN; PENTAMIDINE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VORICONAZOLE;

ABDOMINAL INFECTION; ARTICLE; ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LAMBLIA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; EMPYEMA; FEMALE; FUNGEMIA; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INTESTINE TRANSPLANTATION; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PEDIATRIC SURGERY; PNEUMOCYSTOSIS; PRIORITY JOURNAL; URINARY TRACT INFECTION;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; CANDIDEMIA; CANDIDIASIS, INVASIVE; FEMALE; FUNGEMIA; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFANT; INTESTINE, SMALL; MALE; MYCOSES; TRANSPLANTS; TREATMENT OUTCOME;

EID: 78650150439     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00542.x     Document Type: Article

References (18)

1. Guaraldi G, Cocchi S, Codeluppi M, et al. Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients. Transplantation 2005; 80: 1742-1748.
2. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-2614.
3. Cicalese L, Sileri P, Green M, Abu-Elmagd K, Kocoshis S, Reyes J. Bacterial translocation in clinical intestinal transplantation. Transplantation 2001; 71: 1414-1417.
4. Kalil AC, Dakroub H, Freifeld AG. Sepsis and solid organ transplantation. Curr Drug Targets 2007; 8: 533-541.
5. United States Department of Health and Human Services. OPTN/SRTR Annual Report, Chapter 5: Liver and Intestine Transplantation in the United States, 1997-2006, 2007, 2009.
6. Pirenne J, Kawai M. Intestinal transplantation: evolution in immunosuppression protocols. Curr Opin Organ Transplant 2009; 14: 250-255.
7. Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 2000; 31: 545-553.
8. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1999; 1: 229-236.
9. Ascioglu S, Rex JH, De Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
10. Pirenne J, Kawai M. The protective effect of the liver: does it apply to the bowel too? Transplantation 2006; 81: 978-979.
11. Jugie M, Canioni D, Le Bihan C, et al. Study of the impact of liver transplantation on the outcome of intestinal grafts in children. Transplantation 2006; 81: 992-997.
12. Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus. (spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol 2009; 47: 1942-1946.
13. Pfaller MA, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Diekema DJ. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. J Clin Microbiol 2005; 43: 5208-5213.
14. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-1703.
15. Pappas PG, Rex JH, Lee J, et al; NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-643.
16. Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005; 49: 4555-4560.
17. Van Hal SJ, Marriott DJ, Chen SC, et al; Australian Candidaemia Study Group. Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. Transpl Infect Dis 2009; 11: 122-127.
18. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.